A carregar...
Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators
The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is the largest study of cardiovascular disease in human immunodeficiency virus. Enrolling 7770 participants from 2015 to 2019 with sites across 5 continents, REPRIEVE will assess the effects of a statin as a cardiovascular disease pre...
Na minha lista:
| Publicado no: | J Infect Dis |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7347079/ https://ncbi.nlm.nih.gov/pubmed/32645161 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiaa098 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|